Advertisement
Canada markets open in 7 hours 46 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7305
    +0.0007 (+0.10%)
     
  • CRUDE OIL

    82.94
    +0.13 (+0.16%)
     
  • Bitcoin CAD

    87,963.49
    -3,391.30 (-3.71%)
     
  • CMC Crypto 200

    1,385.74
    -38.36 (-2.69%)
     
  • GOLD FUTURES

    2,329.70
    -8.70 (-0.37%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,435.00
    -229.50 (-1.30%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,653.50
    -806.58 (-2.10%)
     
  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Stocks jump as Dow poised for 6-day winning streak

Stocks pushing higher with the Dow poised for a 6-day winning streak. And oil, it’s rising too. Plus, big earnings reports from Nvidia and Yelp coming out. And, a new Super lux SUV is here: the Rolls Royce Cullinan. Plus, Trumpomomics, with an Iran deal off the table and oil shooting higher, Rick Newman grades the president. Catch The Final Round at 3:55 ET p.m. with Jen Rogers and Yahoo Finance columnist Rick Newman.

Winners and losers

Stocks in the red include Booking Holdings, as the company formerly known as Priceline gave weaker-than-expected earnings and revenue guidance for the second quarter; MannKind, as rising sales of its insulin drug Affreza failed to stem an overall loss for the quarter; and Eastman Kodak, with shares dropping as it intends to raise $50 million in a combined public and private token offering (good luck with that),

Stocks in the green include AMC Networks as it reported better-than expected first-quarter earnings; Green Dot, with the pre-paid debit card company beating on both the top and bottom lines and reporting over 1 million active accounts; and ARMO, with shares surging as Eli Lilly will buy the immuno-oncology firm for about $1.6 billion in an all-cash deal.